Our modeling also predicted opposing roles for FGF signaling in the bladder and uterine cancers: where FGFR2 exerts a tumor-suppressor effect in bladder cancer yet a tumorigenic effect in uterine cancer. This evidence concerns the gene FGFR2 and urinary bladder cancer.